pharma news

April 30, 2021

This Week in Pharma

By MastersConnect

Our roundup of this week's top stories. 

Pfizer acquires Amplyx Pharmaceuticals

Pfizer announced its acquisition of Amplyx Pharmaceuticals, a company it previously invested in during a Series C financing round in December 2019. 

With the acquisition, Pfizer gains fosmanogepix - a drug in phase 2 clinical trials for the treatment of invasive fungal infections. The trials are evaluating the safety and efficacy of intravenous and oral formulations of the treatment for patients suffering life-threatening invasive fungal infections. 

Government injects £37m into Genomics

New funding has been announced by Health and Social Care Secretary Matt Hancock, for genomics projects and data-driven initiatives. The aim is to transform the UK Life Sciences sector. 

Announced at the ABPI Annual Conference, the plan includes £37m of new investments, including £17m to Genomics England projects to support the Genome UK strategy. The additional £20m will be used for investments into data for life sciences research, including clinical trials and funding for cutting edge research, medicine development, and health technology. 

UK buys additional 60m doses of Pfizer/BioNTech vaccine

With the vaccine rolling out across the UK, at over 47.5m vaccines having been administered so far, the Government has secured an additional 60m doses of the Pfizer/BioNTech vaccine to support the autumn COVID-19 vaccination programme. The extra doses are planned for use in preparation for a booster programme based on clinical need, ahead of winter. 

The extra 60m doses brings the total number of Pfizer/BioNTech doses acquired by the UK to 100m, matching the number of secured doses of the AstraZeneca/Oxford University vaccine. 

Versiti launches test for vaccine-related blood clotting issues

Versiti has launched a new antibody test in the US. The tests determine the presence of platelet activating antibodies in the blood - these antibodies are believed to be a key finding following the blood clot cases related to some vaccines. 

Global regulators maintain that the vaccine benefits outweigh the risks associated, though warnings have been issued regarding the possibility of rare side effects such as blood clots.  


More Thoughts

April 15, 2021

This Week in Pharma

Our roundup of the headlines for the week. 

Read more >

August 06, 2021

This Week in Pharma

Our roundup of the week's pharma news...

Read more >

August 20, 2021

This Week in Pharma

Our roundup of the week's top stories...

Read more >